A Genetic Variant in the Body's Cannabis Receptor Was Linked to Higher Rheumatoid Arthritis Risk | Research

The takeaway

In an Iranian population, carriers of the RR genotype in the cannabinoid CB2 receptor gene had more than 2.5 times the risk of developing rheumatoid arthritis compared to other genotypes.

Rheumatology researchers, geneticists studying autoimmune disease, endocannabinoid system scientists.

CB2 receptor RR genotype linked to 2.5x higher rheumatoid arthritis risk

What the researchers found

Logistic regression revealed significant associations between the Q63R polymorphism in the CNR2 gene and rheumatoid arthritis under codominant, dominant, and additive inheritance models. Carriers of the RR genotype had more than a 2.5-fold increased risk of developing RA.

Why it matters

The endocannabinoid system plays a role in immune regulation, and genetic variations in cannabinoid receptors could predispose individuals to autoimmune diseases. This study is the first to examine this specific genetic association in an Iranian population.

The numbers in context

120 RA patients; 120 healthy controls; RR genotype associated with >2.5-fold increased RA risk; significant associations under codominant, dominant, and additive models; TaqMan assay genotyping.

How the study worked

Case-control study of 120 RA patients and 120 healthy controls in Iran, genotyped for the Q63R polymorphism using TaqMan assay. Multiple genetic inheritance models (codominant, dominant, recessive, overdominant, additive) were analyzed using SNPStats software.

What this study cannot tell us

Small sample size (120 per group) limits statistical power. Single ethnic population limits generalizability. No functional studies to explain how the Q63R variant affects CB2 receptor function or immune regulation. Cannot establish causation from genetic association alone.

How to read the evidence

Preliminary: Small case-control study (240 total) in a single ethnic population, representing the first investigation of this association in Iranians.

When this study was published

Published in 2025.

The bigger picture

If cannabinoid receptor genetics influence autoimmune disease risk, it could open new avenues for understanding why some people develop conditions like RA and whether cannabinoid-based interventions could help manage autoimmune inflammation in genetically susceptible individuals.

Questions still open

Does this genetic variant affect how patients respond to cannabinoid-based treatments? Would larger, multi-ethnic studies replicate this association? What is the functional mechanism by which Q63R alters immune regulation?

Common questions

What is the CB2 receptor?

CB2 is one of two main cannabinoid receptors in the body. Unlike CB1 (found mainly in the brain), CB2 is primarily found on immune cells and plays a role in regulating inflammation and immune responses. It's part of the endocannabinoid system.

Does this mean cannabis could treat rheumatoid arthritis?

The study shows a genetic link between a cannabinoid receptor variant and RA risk, suggesting the endocannabinoid system plays a role in RA. However, this does not directly demonstrate that cannabis or cannabinoids would treat the disease. More research is needed to understand the functional implications.

Read the original research

Association of Cannabinoid CB2 Receptor Q63R Variant With Rheumatoid Arthritis in an Iranian Cohort.

International journal of genomics, 2025, 6182868

View on PubMed ↗Publisher’s paper ↗

Citation

Nateghi, Ali; Zamani, Samin; Tahamtan, Alireza. (2025). Association of Cannabinoid CB2 Receptor Q63R Variant With Rheumatoid Arthritis in an Iranian Cohort.. International journal of genomics, 2025, 6182868. https://doi.org/10.1155/ijog/6182868